Entering text into the input field will update the search result below

Sorrento wins FDA go-ahead for early-stage STI-2099 COVID-19 trial

  • Sorrento Therapeutics (NASDAQ:SRNE) has received clearance from the FDA for its Investigational New Drug application (IND) for its Phase 1 study of the safety and pharmacokinetics of intranasal (IN) STI-2099 (COVIDROPS) in both healthy volunteers and patients with mild COVID-19.
  • Initial

Recommended For You

About SRNEQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
SRNEQ--
Sorrento Therapeutics, Inc.